Mahesh Radhakrishnan
Overview
Explore the profile of Mahesh Radhakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gupta D, Radhakrishnan M, Kurhe Y
Metab Brain Dis
. 2014 Apr;
29(3):737-46.
PMID: 24763911
Clinical and preclinical data suggest that diabetes is often associated with anxiety. Insulin, a peptide hormone has been reported to have key functions in the brain and in alleviating several...
12.
Gupta D, Radhakrishnan M, Thangaraj D, Kurhe Y
Eur J Pharmacol
. 2014 Apr;
735:59-67.
PMID: 24747753
Depression and anxiety are the most debilitating mood disorders with poor therapeutic recovery rates. In the last decades, 5-HT3 receptor antagonists have been identified as potential agents for mood disorders....
13.
Bhatt S, Radhakrishnan M, Jindal A, Devadoss T, Dhar A
Indian J Pharmacol
. 2014 Apr;
46(2):191-6.
PMID: 24741192
Aim: The aim of the study was to evaluate a novel 5 HT3 receptor antagonist (6g) on chronic stress induced changes in behavioural and brain oxidative stress parameter in mice....
14.
Gupta D, Kurhe Y, Radhakrishnan M
Physiol Behav
. 2014 Mar;
129:73-8.
PMID: 24582678
Diabetes is a persistent metabolic disorder, which often leads to depression as a result of the impaired neurotransmitter function. Insulin is believed to have antidepressant effects in depression associated with...
15.
Kurhe Y, Radhakrishnan M, Thangaraj D, Gupta D
Indian J Pharmacol
. 2014 Feb;
46(1):100-4.
PMID: 24550593
Objective: To investigate the anti-anxiety activity of "6k", a novel 5-hydroxytryptamine type 3 (5-HT₃) receptor antagonist in in mice. Materials And Methods: Anti-anxiety activity of "6k" (1, 2, and 4...
16.
Gupta D, Radhakrishnan M, Bhatt S, Kurhe Y
Indian J Psychol Med
. 2013 Nov;
35(3):290-8.
PMID: 24249933
Background: Depression is a neurological disorder characterized by sad mood, loss of pleasure, agitation and retardation. Though most relevant neuronal pathophysiology is characterized by decrease in monoamine namely; serotonin (5-HT),...
17.
Kurhe Y, Radhakrishnan M, Gupta D, Devadoss T
J Pharm Pharmacol
. 2013 Nov;
66(1):122-32.
PMID: 24180368
Objectives: The inconsistent therapeutic outcome necessitates identifying novel compounds for the treatment of depression. Therefore, the present study is aimed at evaluating the antidepressant-like effects of a novel 5-HT3 receptor...
18.
Vas L, Pai R, Radhakrishnan M
Pain Pract
. 2012 Apr;
13(1):76-88.
PMID: 22494480
Objective: To explore the potential diagnostic utility of musculoskeletal ultrasonography (USG) changes in complex regional pain syndrome type 1 (CRPS-1) of the upper extremity. Methods: With informed consent, 18 consecutive...
19.
Ramamoorthy R, Radhakrishnan M, Borah M
Behav Pharmacol
. 2008 Jan;
19(1):29-40.
PMID: 18195592
The present behavioural investigation evaluates the antidepressant potential of ondansetron (OND), a widely used (in management of cancer chemotherapy-induced nausea and emesis) 5-HT3 receptor antagonist. Separate groups of mice received...
20.
Sharma A, Pandey A, Radhakrishnan M, Kumbhani D, Das H, Desai N
Indian J Gastroenterol
. 2003 Mar;
22(1):29-30.
PMID: 12617454
A 2-year-old male child, who was operated on 18 months earlier for tuberculous meningitis with hydrocephalus by placement of a ventriculo-peritoneal shunt, presented with the lower end of the shunt...